Milsaperidone (VHX-896) vs Quetiapine (Seroquel XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Quetiapine (Seroquel XR)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00640601 · Phase 3 · completed
This was a nonrandomized, single-group, open-label study of 295 treated participants, without a placebo or active comparator. Although 56.88% were reported to have improved clinical benefit on the primary CGI-CB measure, the uncontrolled design cannot determine how much of the improvement was due to quetiapine rather than other factors.
Next expected readout: February 2032 · NCT07152184 (registry estimate)
Reported efficacy
Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8) (not_applicable)
Result source: NCT00640601
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Milsaperidone (VHX-896) | Quetiapine (Seroquel XR) |
|---|---|---|
| PANSS total, change | —Not reported | -24 vs -15.9−8.1 vs placeboNCT018103801 other result
|
| CGI-S, change | —Not reported | -1.4 vs -0.9−0.5 vs placeboNCT018103801 other result
|
| PANSS response | —Not reported | 62.7% vs 32.1%+30.6 vs placeboNCT01810380 |
| PSP, change | —Not reported | 15.3 vs 9.4+5.9 vs placeboNCT01810380 |
| Relapse (% of patients) | —Not reported | —Not posted · NCT00159770 |
PANSS total, change
- Milsaperidone (VHX-896)
- —Not reported
- Quetiapine (Seroquel XR)
- -24 vs -15.9−8.1 vs placeboNCT01810380
1 other result
- 102.3 vs 100.5 NCT00640562
CGI-S, change
- Milsaperidone (VHX-896)
- —Not reported
- Quetiapine (Seroquel XR)
- -1.4 vs -0.9−0.5 vs placeboNCT01810380
1 other result
- -1.5 vs -1.0 NCT00640562
PANSS response
- Milsaperidone (VHX-896)
- —Not reported
- Quetiapine (Seroquel XR)
- 62.7% vs 32.1%+30.6 vs placeboNCT01810380
PSP, change
- Milsaperidone (VHX-896)
- —Not reported
- Quetiapine (Seroquel XR)
- 15.3 vs 9.4+5.9 vs placeboNCT01810380
Relapse (% of patients)
- Milsaperidone (VHX-896)
- —Not reported
- Quetiapine (Seroquel XR)
- —Not posted · NCT00159770
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Quetiapine (Seroquel XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Quetiapine (Seroquel XR) |
|---|---|
| Dropout rate | 38%a NCT00640601 · Phase 3 show 7 more results16.5% NCT00640562 · Phase 3 —Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence —Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 20% NCT00954122 · Phase 4 · registry result, not featured evidence 30.2% NCT00779506 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 20.8%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 14.6%a NCT00640601 · Phase 3 show 7 more results7.3% NCT00640562 · Phase 3 —Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence —Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 2.9% NCT00954122 · Phase 4 · registry result, not featured evidence 4.2% NCT00779506 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 2.6%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 11.2%a NCT00640601 · Phase 3 show 7 more results3.7% NCT00640562 · Phase 3 0%Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence 0%Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 2.9% NCT00954122 · Phase 4 · registry result, not featured evidence 0% NCT00779506 · Phase 4 · registry result, not featured evidence 1.3%Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence —Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 5 more resultssomnolence 3.2% delusion 1.6% dizziness 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence psychotic disorder 1.6% sedation 1.6% sleep disorder 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence constipation 25.5% insomnia 23.4% sedation 12.8% NCT00779506 · Phase 4 · registry result, not featured evidence somnolence 22.2% (placebo 5%) weight increased 13.1% (placebo 3.7%) dizziness 11.8% (placebo 0.6%) NCT01810380 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Quetiapine (Seroquel XR)
show 2 more results
show 1 more result
show 1 more result
show 2 more results
show 1 more result
show 1 more result
+ 22 further endpoints in the CSV export.
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Quetiapine (Seroquel XR)
Marketed by Cheplapharm Arzneimittel GmbH and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.
Quetiapine (Seroquel XR): no structured comparison results are available for Bipolar Disorder.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Quetiapine (Seroquel XR)'s landscape